Transcriptome Analysis Identifies Biomarkers for the Diagnosis and Management of Psoriasis Complicated with Depression

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
   PubMed Web of Science ®Google Scholar
• Damiani G, Radaeli A, Olivini A, Calvara-Pinton P, Malerba M. Increased airway inflammation in patients with psoriasis. Br J Dermatol. 2016;175(4):797–799. doi:10.1111/bjd.14546
   PubMed Web of Science ®Google Scholar
• Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120–2130. doi:10.1016/j.jaci.2018.11.038
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi:10.1016/S0140-6736(07)61128-3
   PubMed Web of Science ®Google Scholar
• Kumar S, Han J, Li T, Qureshi AA. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol. 2013;27(10):1293–1298. doi:10.1111/jdv.12001
   PubMed Web of Science ®Google Scholar
• Zafiriou E, Daponte AI, Siokas V, et al. Depression and obesity in patients with psoriasis and psoriatic arthritis: is IL-17-mediated immune dysregulation the connecting link? Front Immunol. 2021;12:699848. doi:10.3389/fimmu.2021.699848
   PubMed Web of Science ®Google Scholar
• Patel N, Nadkarni A, Cardwell LA, et al. Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol. 2017;18(5):613–620. doi:10.1007/s40257-017-0279-8
   PubMed Web of Science ®Google Scholar
• Wang X, Li Y, Wu L, et al. Dysregulation of the gut-brain-skin axis and key overlapping inflammatory and immune mechanisms of psoriasis and depression. Biomed Pharmacother. 2021;137:111065. doi:10.1016/j.biopha.2020.111065
   PubMed Web of Science ®Google Scholar
• Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–991. doi:10.1038/jid.2014.530
   PubMed Web of Science ®Google Scholar
• Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542–1551. doi:10.1038/jid.2013.508
   PubMed Web of Science ®Google Scholar
• Lamb RC, Matcham F, Turner MA, et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol. 2017;176(4):1028–1034. doi:10.1111/bjd.14833
   PubMed Web of Science ®Google Scholar
• Korman AM, Hill D, Alikhan A, Feldman SR. Impact and management of depression in psoriasis patients. Expert Opin Pharmacother. 2016;17(2):147–152. doi:10.1517/14656566.2016.1128894
   PubMed Web of Science ®Google Scholar
• Singh S, Taylor C, Kornmehl H, Armstrong AW. Psoriasis and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):425–440 e422. doi:10.1016/j.jaad.2017.05.019
   PubMed Web of Science ®Google Scholar
• Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34. doi:10.1038/nri.2015.5
   PubMed Web of Science ®Google Scholar
• Roman M, Irwin MR. Novel neuroimmunologic therapeutics in depression: a clinical perspective on what we know so far. Brain Behav Immun. 2020;83:7–21. doi:10.1016/j.bbi.2019.09.016
   PubMed Web of Science ®Google Scholar
• Beurel E, Toups M, Nemeroff CB. the bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020;107(2):234–256. doi:10.1016/j.neuron.2020.06.002
   PubMed Web of Science ®Google Scholar
• Cheng Y, Desse S, Martinez A, et al. TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. Brain Behav Immun. 2018;69:556–567. doi:10.1016/j.bbi.2018.02.003
   PubMed Web of Science ®Google Scholar
• Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2017;60:1–12. doi:10.1016/j.bbi.2016.03.010
   PubMed Web of Science ®Google Scholar
• Borsini A, Alboni S, Horowitz MA, et al. Rescue of IL-1β-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants. Brain Behav Immun. 2017;65:230–238. doi:10.1016/j.bbi.2017.05.006
   PubMed Web of Science ®Google Scholar
• Baran P, Hansen S, Waetzig GH, et al. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem. 2018;293(18):6762–6775. doi:10.1074/jbc.RA117.001163
   PubMed Web of Science ®Google Scholar
• Schiweck C, Valles-Colomer M, Arolt V, et al. Depression and suicidality: a link to premature T helper cell aging and increased Th17 cells. Brain Behav Immun. 2020;87:603–609. doi:10.1016/j.bbi.2020.02.005
   PubMed Web of Science ®Google Scholar
• Beurel E, Lowell JA. Th17 cells in depression. Brain Behav Immun. 2018;69:28–34. doi:10.1016/j.bbi.2017.08.001
   PubMed Web of Science ®Google Scholar
• Siffrin V, Radbruch H, Glumm R, et al. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity. 2010;33(3):424–436. doi:10.1016/j.immuni.2010.08.018
   PubMed Web of Science ®Google Scholar
• Anderson G. Editorial (Thematic Issue: the kynurenine and melatonergic pathways in psychiatric and CNS disorders). Curr Pharm Des. 2016;22(8):947–948. doi:10.2174/1381612822999160104143932
   PubMed Web of Science ®Google Scholar
• Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
   PubMed Web of Science ®Google Scholar
• Xia X, Cao G, Sun G, et al. GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis. J Clin Invest. 2020;130(10):5180–5196. doi:10.1172/JCI129269
   PubMed Web of Science ®Google Scholar
• Liu T, Li S, Ying S, et al. The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol. 2020;11:594735. doi:10.3389/fimmu.2020.594735
   PubMed Web of Science ®Google Scholar
• Bigler J, Rand HA, Kerkof K, Timour M, Russell CB, Brandner JM. Cross-study homogeneity of psoriasis gene expression in skin across a large expression range. PLoS One. 2013;8(1):e52242. doi:10.1371/journal.pone.0052242
   PubMed Web of Science ®Google Scholar
• Kim J, Bissonnette R, Lee J, et al. The spectrum of mild to severe psoriasis vulgaris is defined by a common activation of IL-17 pathway genes, but with key differences in immune regulatory genes. J Invest Dermatol. 2016;136(11):2173–2182. doi:10.1016/j.jid.2016.04.032
   PubMed Web of Science ®Google Scholar
• Bertelsen T, Ljungberg C, Litman T, et al. IκBζ is a key player in the antipsoriatic effects of secukinumab. J Allergy Clin Immunol. 2020;145(1):379–390. doi:10.1016/j.jaci.2019.09.029
   PubMed Web of Science ®Google Scholar
• Savitz J, Frank MB, Victor T, et al. Inflammation and neurological disease-related genes are differentially expressed in depressed patients with mood disorders and correlate with morphometric and functional imaging abnormalities. Brain Behav Immun. 2013;31:161–171. doi:10.1016/j.bbi.2012.10.007
   PubMed Web of Science ®Google Scholar
• Leday GGR, Vértes PE, Richardson S, et al. Replicable and coupled changes in innate and adaptive immune gene expression in two case-control studies of blood microarrays in major depressive disorder. Biol Psychiatry. 2018;83(1):70–80. doi:10.1016/j.biopsych.2017.01.021
   PubMed Web of Science ®Google Scholar
• Su W, Zhao Y, Wei Y, et al. Exploring the pathogenesis of psoriasis complicated with atherosclerosis via microarray data analysis. Front Immunol. 2021;12:667690. doi:10.3389/fimmu.2021.667690
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431–432. doi:10.1093/bioinformatics/btq675
   PubMed Web of Science ®Google Scholar
• Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(suppl_2):W214–W220. doi:10.1093/nar/gkq537
   PubMed Web of Science ®Google Scholar
• Han H, Cho J-W, Lee S, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46(D1):D380–D386. doi:10.1093/nar/gkx1013
   PubMed Web of Science ®Google Scholar
• Gonzalez-Parra S, Dauden E. Psoriasis and depression: the role of inflammation. Actas Dermosifiliogr. 2019;110(1):12–19. doi:10.1016/j.ad.2018.05.009
   PubMed Web of Science ®Google Scholar
• Damiani G, Cazzaniga S, Conic RR, Naldi L, Griseta V. Pruritus characteristics in a large Italian cohort of psoriatic patients. J Eur Acad Dermatol Venereol. 2019;33(7):1316–1324. doi:10.1111/jdv.15539
   PubMed Web of Science ®Google Scholar
• Nowowiejska J, Baran A, Lewoc M, et al. The assessment of risk and predictors of sleep disorders in patients with psoriasis—a questionnaire-based cross-sectional analysis. J Clin Med. 2021;10(4):664. doi:10.3390/jcm10040664
   PubMed Web of Science ®Google Scholar
• Myers B, Reddy V, Brownstone N, et al. Sleep and the gut microbiome in psoriasis: clinical implications for disease progression and the development of cardiometabolic comorbidities. J Psoriasis Psoriatic Arthritis. 2021;6(1):27–37. doi:10.1177/2475530320964781
   PubMedGoogle Scholar
• Holsken S, Krefting F, Schedlowski M, Sondermann W. Common fundamentals of psoriasis and depression. Acta Derm Venereol. 2021;101(11):adv00609. doi:10.2340/actadv.v101.565
   PubMedGoogle Scholar
• Talamonti M, Malara G, Natalini Y, et al. Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study. Acta Derm Venereol. 2021;101(3):adv00422. doi:10.2340/00015555-3712
   PubMedGoogle Scholar
• Aleem D, Tohid H. Pro-inflammatory cytokines, biomarkers, genetics and the immune system: a mechanistic approach of depression and psoriasis. Rev Colomb Psiquiatr. 2018;47(3):177–186. doi:10.1016/j.rcp.2017.03.002
   Google Scholar
• Cai N, Choi KW, Fried EI. Reviewing the genetics of heterogeneity in depression: operationalizations, manifestations and etiologies. Hum Mol Genet. 2020;29(R1):R10–R18. doi:10.1093/hmg/ddaa115
   PubMed Web of Science ®Google Scholar
• Galecka M, Bliźniewska-Kowalska K, Orzechowska A, et al. Inflammatory versus anti-inflammatory profiles in major depressive disorders—the role of IL-17, IL-21, IL-23, IL-35 and Foxp3. J Pers Med. 2021;11(2):66. doi:10.3390/jpm11020066
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled Phase III trial. J Am Acad Dermatol. 2010;63(3):457–465. doi:10.1016/j.jaad.2009.09.014
   PubMed Web of Science ®Google Scholar
• Sergi C, Kahl P, Otto HF. Immunohistochemical localization of transforming growth factor-α and epithelial growth factor receptor in human fetal developing skin, psoriasis and restrictive dermopathy. Pathol Oncol Res. 2000;6(4):250–255. doi:10.1007/BF03187327
   PubMedGoogle Scholar
• Dai X, Murakami M, Shiraishi K, et al. EGFR ligands synergistically increase IL-17A-induced expression of psoriasis signature genes in human keratinocytes via IκBζ and Bcl3. Eur J Immunol. 2022;52(6):994–1005. doi:10.1002/eji.202149706
   PubMed Web of Science ®Google Scholar
• Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol. 2006;6:1298–1304. doi:10.1016/j.intimp.2006.03.015
   PubMed Web of Science ®Google Scholar
• Chen B, Li C, Chang G, Wang H. Dihydroartemisinin targets fibroblast growth factor receptor 1 (FGFR1) to inhibit interleukin 17A (IL-17A)-induced hyperproliferation and inflammation of keratinocytes. Bioengineered. 2022;13(1):1530–1540. doi:10.1080/21655979.2021.2021701
   PubMed Web of Science ®Google Scholar
• Byrd VM, Kilkenny DM, Dikov MM, et al. Fibroblast growth factor receptor-1 interacts with the T-cell receptor signalling pathway. Immunol Cell Biol. 2003;81(6):440–450. doi:10.1046/j.1440-1711.2003.01199.x
   PubMed Web of Science ®Google Scholar
• Yang J, Meyer M, Müller AK, et al. Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis. J Cell Biol. 2010;188(6):935–952. doi:10.1038/jid.2013.508
   PubMed Web of Science ®Google Scholar
• Turner CA, Gula EL, Taylor LP, Watson SJ, Akil H. Antidepressant-like effects of intracerebroventricular FGF2 in rats. Brain Res. 2008;1224:63–68. doi:10.1016/j.bbi.2018.02.003
   PubMed Web of Science ®Google Scholar
• Aurbach EL, Inui EG, Turner CA, et al. Fibroblast growth factor 9 is a novel modulator of negative affect. Proc Natl Acad Sci USA. 2015;112(38):11953–11958. doi:10.1111/bjd.14546
   PubMed Web of Science ®Google Scholar
• Xu Y-H, Zhu Y, Zhu YY, et al. Abnormalities in FGF family members and their roles in modulating depression-related molecules. Eur J Neurosci. 2021;53(1):140–150. doi:10.1172/JCI129269
   PubMed Web of Science ®Google Scholar
• Rollman O, Jensen UB, Östman A, et al. Platelet Derived Growth Factor (PDGF) responsive epidermis formed from human keratinocytes transduced with the PDGFβ receptor gene. J Invest Dermatol. 2003;120(5):742–749. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Jha MK, Minhajuddin A, Gadad BS, Trivedi MH. Platelet-derived growth factor as an antidepressant treatment selection biomarker: higher levels selectively predict better outcomes with bupropion-SSRI combination. Int J Neuropsychopharmacol. 2017;20(11):919–927. doi:10.1016/S0140-6736(07)61128-3
   PubMed Web of Science ®Google Scholar
• Sharma J, Larkin J 3rd. Therapeutic implication of SOCS1 modulation in the treatment of autoimmunity and cancer. Front Pharmacol. 2019;10:324. doi:10.3389/fphar.2019.00324
   PubMed Web of Science ®Google Scholar
• Yu C-F, Peng W-M, Schlee M, et al. SOCS1 and SOCS3 target IRF7 degradation to suppress TLR7-mediated type I IFN production of human plasmacytoid dendritic cells. J Immunol. 2018;200(12):4024–4035. doi:10.4049/jimmunol.1700510
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Shinagawa S, Nagata T, Shigeta M, Kondo K. Suppressors of cytokine signaling are decreased in major depressive disorder patients. J Pers Med. 2022;12(7):1040. doi:10.3390/jpm12071040
   PubMed Web of Science ®Google Scholar
• Kromer C, Mohr J, Celis D, et al. Screening for depression in psoriasis patients during a dermatological consultation: a first step towards treatment. J Dtsch Dermatol Ges. 2021;19:1451–1461. doi:10.1111/ddg.14532
   Web of Science ®Google Scholar
• Gerdes S, Wilsmann-Theis D, Celis D, Kromer C, Mossner R. Two questions may be enough - screening for depression in patients with psoriasis: a multicenter study. J Dtsch Dermatol Ges. 2020;18:1115–1125. doi:10.1111/ddg.14203
   Web of Science ®Google Scholar